Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis

Critical Care Medicine

Volumn 38, Issue 12, 2010, Pages 2401-2408

  Lamontagne, François ^a   Briel, Matthias ^b,c   Duffett, Mark ^c   Fox Robichaud, Alison ^c   Cook, Deborah J ^c   Guyatt, Gordon ^c   Lesur, Olivier ^a   Meade, Maureen O ^c  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

bias; clinical relevance; evidence based medicine; research methodology; review literature as a topic; sepsis; translational research

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE MAGNESIUM; ALLOPURINOL; ALPHA TOCOPHEROL; ARACHIDONIC ACID DERIVATIVE; ASCORBIC ACID; BETA CAROTENE; COPPER; CORTICOSTATIN; DOCOSAHEXAENOIC ACID; EBSELEN; ENDOTOXIN ANTIBODY; GLUCOCORTICOID; GLUTAMINE; GLUTATHIONE; HEPARIN; ICOSAPENTAENOIC ACID; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 ANTIBODY; MELATONIN; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; PROSTAGLANDIN E; SELENIUM; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOMODULIN; UNINDEXED DRUG; VASOPRESSIN; ZINC;

ANIMAL EXPERIMENT; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; EMBASE; HUMAN; MEDICAL RESEARCH; MEDLINE; META ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK; SEPSIS; SYSTEMATIC REVIEW;

EID: 78650304989     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181fa0468     Document Type: Review

References (21)

1. Dellinger RP, Levy MM, Carlet JM, et al: Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 [erratum appears in Crit Care Med 2008; 36:1394-1396]. Crit Care Med 2008; 36:296-327
2. Hollenberg SM, Ahrens TS, Annane D, et al: Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32:1928-1948
3. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial: The E5 Sepsis Study Group [erratum appears in Crit Care Med 1995; 23: 1616]. Crit Care Med 1995; 23:994-1006
4. Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein: The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334:1697-1702
5. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial CHESS Trial Study Group. Ann Intern Med 1994; 121:1-5
6. Dyson A, Singer M: Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37:S30-S37
7. Esmon CT: Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 2004; 32:S219-S222
8. Sandercock P, Roberts I: Systematic reviews of animal experiments. Lancet 2002; 360:586
9. Roberts I, Kwan I, Evans P, et al: Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. BMJ 2002; 324:474-476
10. Piper RD, Cook DJ, Bone RC, et al: Introducing critical appraisal to studies of animal models investigating novel therapies in sepsis. Crit Care Med 1996; 24:2059-2070
11. Macleod MR, van der Worp HB, Sena ES, et al: Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008; 39: 2824-2829
12. Crossley NA, Sena E, Goehler J, et al: Empirical evidence of bias in the design of experimental stroke studies: A metaepidemiologic approach. Stroke 2008; 39:929-934
13. Bebarta V, Luyten D, Heard K: Emergency medicine animal research: Does use of randomization and blinding affect the results? [erratum appears in Acad Emerg Med 2003; 10:1410]. Acad Emerg Med 2003; 10: 684-687
14. Horn J, de Haan RJ, Vermeulen M, et al: Nimodipine in animal model experiments of focal cerebral ischemia: A systematic review. Stroke 2001; 32:2433-2438
15. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339:b2535
16. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174
17. Horn J, Limburg M: Calcium antagonists for ischemic stroke: A systematic review. Stroke 2001; 32:570-576
18. Lopez A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30
19. Investigators N-SS, Finfer S, Chittock DR, et al: Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360:1283-1297
20. Montori VM, Devereaux PJ, Adhikari NK, et al: Randomized trials stopped early for benefit: A systematic review. JAMA 2005; 294: 2203-2209
21. Guyatt GH, Oxman AD, Vist GE, et al: GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926